checkAd

     121  0 Kommentare Idorsia appoints Guy Braunstein to Chief Medical Officer and Alberto Gimona to Head of Global Clinical Development

    Ad hoc announcement pursuant to Art. 53 LR

    Idorsia appoints Guy Braunstein to Chief Medical Officer and Alberto Gimona to Head of Global Clinical Development

    • Guy Braunstein, currently Head of Global Clinical Development, to assume newly created role of Chief Medical Officer and remain a member of the Idorsia Executive Committee
    • Alberto Gimona, currently Head of Therapeutic Area Units, to succeed Guy Braunstein and join the Idorsia Executive Committee

    Allschwil, Switzerland – January 24, 2022
    Idorsia Ltd (SIX: IDIA) today announced the appointment of Guy Braunstein, who has served as Head, Global Clinical Development since the creation of Idorsia and before, since 2009 at Actelion, to a newly created role – Chief Medical Officer (CMO) and affirms that Guy will continue to serve as a member of the Idorsia Executive Committee (IEC) in this new position. Alberto Gimona, who has served as the Head of Therapeutic Area Units since February 2019 within Global Clinical Development, will succeed Guy as Head of Global Clinical Development and join the IEC. Both roles are effective immediately.

    The CMO role will ensure that Idorsia’s approach to medical governance and its policies and procedures are globally aligned and consistent across Drug Discovery, Clinical Development, Pharmaceutical Development and Global and Local Medical Affairs.

    Jean-Paul Clozel, M.D. and Chief Executive Officer of Idorsia commented:
    “Guy has been integral to rapidly advancing Idorsia’s clinical pipeline and the approval of our first product, less than 5 years after the company’s inception. As Idorsia enters a new phase, becoming a fully-fledged biopharmaceutical company with marketed products, we can benefit from a dedicated focus on medical governance. The CMO office will unify the company’s quality and governance standards to confirm an uncompromisingly ethical and scientifically rigorous approach along the lifecycle of all products in Idorsia’s pipeline, ensuring appropriate and safe use of Idorsia’s medicinal products and medical ethics in engagement with various stakeholders.”

    Lesen Sie auch

    Jean-Paul continued:
    “As such, the Board and I have agreed to create the role of Chief Medical Officer, reporting directly to me. With his wealth of experience and his deep knowledge of the Idorsia pipeline, Guy is in the perfect position to take on this new role, and as a member of the IEC, he will continue to help steer the future of Idorsia.”

    Seite 1 von 3


    globenewswire
    0 Follower
    Autor folgen
    Verfasst von globenewswire
    Idorsia appoints Guy Braunstein to Chief Medical Officer and Alberto Gimona to Head of Global Clinical Development Ad hoc announcement pursuant to Art. 53 LR Idorsia appoints Guy Braunstein to Chief Medical Officer and Alberto Gimona to Head of Global Clinical Development Guy Braunstein, currently Head of Global Clinical Development, to assume newly created …